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Abstract
Background This study was performed to test the therapeutic potential of obestatin, an autocrine anabolic factor regulating
skeletal muscle repair, to ameliorate the Duchenne muscular dystrophy (DMD) phenotype.
Methods and results Using a multidisciplinary approach, we characterized the ageing-related preproghrelin/GPR39 expres-
sion patterns in tibialis anterior (TA) muscles of 4-, 8-, and 18-week-old mdx mice (n = 3/group) and established the effects of
obestatin administration at this level in 8-week-old mdx mice (n = 5/group). The findings were extended to in vitro effects on
human immortalized DMD myotubes. An analysis of TAs revealed an age-related loss of preproghrelin expression, as precursor
of obestatin, in mdx mice. Administration of obestatin resulted in a significant increase in tetanic specific force (33.0% ± 1.5%,
P < 0.05), compared with control mdx mice. Obestatin-treated TAs were characterized by reduction of fibres with centrally
located nuclei (10.0% ± 1.2%, P < 0.05) together with an increase in the number of type I fibres (25.2% ± 1.7%, P < 0.05) as-
sociated to histone deacetylases/myocyte enhancer factor-2 and peroxisome proliferator-activated receptor-gamma coactiva-
tor 1α axis, and down-regulation of ubiquitin E3-ligases by inactivation of FoxO1/4, indexes of muscle atrophy. Obestatin
reduced the level of contractile damage and tissue fibrosis. These observations correlated with decline in serum creatine ki-
nase (58.8 ± 15.2, P < 0.05). Obestatin led to stabilization of the sarcolemma by up-regulation of utrophin, α-syntrophin, β-
dystroglycan, and α7β1-integrin proteins. These pathways were also operative in human DMD myotubes.
Conclusions These results highlight the potential of obestatin as a peptide therapeutic for preserving muscle integrity in
DMD, thus allowing a better efficiency of gene or cell therapy in a combined therapeutic approach.
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Introduction
Duchenne muscular dystrophy (DMD) is a degenerative disor-
der caused by mutations in the X-linked dystrophin gene, af-
fecting 1 in 3500 newborn males. DMD patients suffer from
progressive muscle wasting with clinical symptoms first de-
tected between 2 and 5 years of age. In skeletal muscle, the
dystrophin-glycoprotein complex is localized within the
membrane along muscle fibres and at myotendinous and
neuromuscular junctions (NMJs). This complex includes
dystroglycans, sarcoglycans, and syntrophins that link the
muscle cell cytoskeleton to the extracellular matrix and main-
tains sarcolemma integrity.1 Dystrophin deficiency results in
the disruption of the dystrophin glycoprotein complex-
extracellular matrix linkage that leads to the loss of sarco-
lemma integrity and tearing of the sarcolemma. This causes
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an influx of Ca2+ into muscle cells, activation of Ca2+-depen-
dent proteases, and muscle degeneration during contrac-
tion.2 Muscle degeneration is accompanied by regeneration
through the activation of muscle satellite cells; however, re-
generative capacity in DMD patients becomes progressively
impaired, associated in humans at least partly to an exhaus-
tion of satellite cell proliferative potential. The muscle itself
cannot counteract this structural damage, ultimately leading
to loss of muscle fibres, infiltration of adipose tissue, and in-
creased fibrosis, all resulting in loss of muscle mass and func-
tion.3 As the disease progresses, patients lose ambulation in
their early teens, along with scoliosis, contractures, respira-
tory, and cardiac impairment, and their life expectancy is re-
duced to 30–40 years.4–6
Different potential therapeutic approaches are presently
undergoing clinical evaluation.5,7,8 However, current strate-
gies for the treatment of dystrophic skeletal muscle, whether
these are gene or cell-based, face the bottleneck that
targeted fibres often degenerate before they are fully res-
cued, thus causing the loss of the therapeutic agent.9–11 A po-
tential approach would be the use of autocrine/paracrine
signals involved in muscle regeneration to enhance endoge-
nous satellite cell function and temporarily protect the fibres
from degenerating while gene or cell therapy is applied. In
this sense, obestatin, a 23-amino acid peptide derived from
a polypeptide called preproghrelin, exerts an autocrine func-
tion in skeletal muscle to control the myogenic programme
through the G protein-coupled receptor GPR39.12 In addition,
obestatin injection or its overexpression in damaged muscle
significantly improves muscle regeneration in healthy mice.13
Mechanistically, in injured muscles from healthy mice,
obestatin enhances muscle regeneration by regulating multi-
ple steps of myogenesis: myoblast proliferation, cell cycle
exit, differentiation, and recruitment-to fuse and form multi-
nucleated hypertrophic myotubes. This action is co-ordinated
by the interplay between G protein-dependent and β-
arrestin-dependent mechanisms.14 The obestatin-associated
mitogenic action is determined by G protein-dependent acti-
vation defining the intricate pathways related to the ERK1/2
and JunD axis, and the transactivation of epidermal growth
factor receptor through the β-arrestin signal complex deter-
mines the cell cycle exit and the development and progres-
sion of differentiation through a kinase hierarchy
determined by the Akt, Ca2+/calmodulin-dependent protein
kinase II (CaMKII), c-Jun, and p38 axes. In addition to its
well-established role in the control of muscle regeneration,
obestatin participates in the specification of muscle fibre
identity by inducing skeletal muscle remodelling toward an
oxidative phenotype more resistant to damage and enhanced
in muscle strength.15 Obestatin acts through both class II his-
tone deacetylases (HDAC)/myocyte enhancer factor-2 (Mef2)
and peroxisome proliferator-activated receptor-gamma coac-
tivator 1α (PGC1α) mechanisms, thereby controlling the es-
tablishment of oxidative muscle fibres. The obestatin/GPR39
system is able to counteract deregulations in proteostasis,
e.g. those associated to glucocorticoid-induced myotube at-
rophy, and to restore efficient basal homoeostasis.16 In cell
transplantation therapy, e.g. myoblast-based therapy by
xenotransplanting primary human myoblasts into immunode-
ficient mice, obestatin not only enhances the efficiency of en-
graftment but also facilitates an even distribution of
myoblasts within the host muscle, probably by enhancing
migration.17
In this study, we assessed the therapeutic potential of the
factor obestatin for focal treatment of dystrophic DMD mus-
cles using in the dystrophin deficient mdx mouse. We found
that, in addition to the established role in the control of mus-
cle regeneration, obestatin-treated mdx mice show skeletal
muscle remodelling toward an oxidative phenotype, with im-
proved muscle strength and reduced skeletal muscle pathol-
ogy. We also show that after obestatin treatment, there is
an increased expression of two critical sarcolemma com-
plexes in dystrophin-deficient skeletal muscle that have been
shown to modify disease progression: the utrophin glycopro-
tein complex and α7β1 integrin. These pathways were also
operative in a human context, because some features of
the DMD phenotype were reversed by obestatin in human
immortalized DMD myoblasts/myotubes. Together, our find-
ings indicate that obestatin is a promising candidate to opti-
mize current treatments for DMD.
Material and methods
Materials
Rat/mouse obestatin and human obestatin was obtained
from BCN Peptides (Barcelona, Spain). Antibodies used are
listed in Table S1. All other chemical reagents were from
Sigma Chemical Co. (St. Louis, MO, USA).
Animals
This study used 4-, 8-, and 18-week-old male C57BL/10ScSn-
Dmdmdx/J mice (mdx mice) obtained from The Jackson Labo-
ratory (Bar Harbor, ME, USA). For protein expression assays,
we used 4-, 8-, and 18-week-old male mdx mice. To examine
the effects of exogenous obestatin in dystrophic muscles, 8-
week-old male mdx mice were used. Experiments were per-
formed in accordance with the University of Santiago de
Compostela guidelines for animal handling and animal care
as determined by the University of Santiago de Compostela
Animal Care Committee according to the guidelines of the
Spanish Royal Decree 53/2013, Directive 2010/63/EU, and
FELASA Guidelines.
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Obestatin dosing
The experimental protocol used in the present work was pre-
viously described.15 Animals, 8-week-old male mdx mice,
were assigned to one of the following experimental groups
(n = 5 per group): (i) control group {[vehicle administration:
phosphate-buffered saline (PBS)]; n = 5} and (ii) obestatin-
treated group (n = 5). Obestatin treatment was performed
via injection of 20 μL of obestatin solution in PBS (pH 6.3)
(500 nmol/kg body weight) into the target muscles every
72 h during 30 days. Control group was treated with 20 μL
of PBS under the same conditions. Injections were performed
inserting the needle of a 0.3 mL/29 gauge syringe (Terumo
Myjector V-100 insulin syringe) at 1 mm in the distal part of
the muscle, in a region that is not taken into account for his-
tological analysis, as previously described.15 After 30 days,
mice were anaesthetized by intraperitoneal injection of
2.2 mg ketamine/0.4 mg xylazine/0.22 mg acepromazine
per 10 g of animal body weight.13 Muscle force was mea-
sured, and blood samples were collected from tail bleeds in
all animals. Animals were sacrificed by cervical dislocation un-
der anaesthesia, and tibialis anterior (TA) muscles from differ-
ent groups were excised, weighed, and processed for
subsequent analyses.
Measurements of muscle force in vivo
Muscle force was measured in a living animal as previously
described.15 Briefly, TA muscle contractile performance was
measured in vivo in anaesthetized mice using 1305A Whole
Animal System (Aurora Scientific, Inc., ON, Canada). TA con-
tractions were evoked by electrical stimulation of the com-
mon peroneal nerve using one electrode placed on the
popliteal fossa. The force-frequency curves were determined
by stepwise increasing stimulation frequency, pausing 120 s
between stimuli to avoid effects due to fatigue. Developed
force was expressed as specific force.
Cell culture and differentiation of human
immortalized Duchenne muscular dystrophy
myoblasts
Muscle biopsy was obtained from the MyoBank-AFM bank of
tissues for research, a partner in the EU network
EuroBioBank, in accordance with European recommendations
and French legislation. Deltoid muscle biopsy was obtained
from a 6-year-old male patient suffering from DMD (duplica-
tion of exon 2). Primary cells were isolated from the deltoid
muscle as described previously.18,19 Myoblasts are cultivated
in growth medium containing Medium 199 : Dulbecco’s mod-
ified Eagle’s medium (1:4, v:v; Lonza, Pontevedra, Spain) sup-
plemented with 20% foetal bovine serum (v/v), 25 μg/μL
fetuin, 5 ng/mL hEGF, 0.5 ng/mL bFGF, 0.2 μg/mL dexameth-
asone (Sigma-Aldrich, MO, USA), and 50 μg/mL gentamycin
(Invitrogen, Thermo Fisher Scientific, MA, USA). Immortaliza-
tion and selection processes were performed as previously
described.20 Briefly, TERT and Cdk4 cDNAs were cloned into
different lentiviral vectors containing puromycin and neomy-
cin selection markers, respectively. Myoblasts were trans-
duced with both TERT and Cdk4 lentiviral vectors, with a
MOI of 3–5 in the presence of 4 μg/mL of polybrene
(Sigma-Aldrich). Transduced cell cultures were selected with
puromycin (0.2 μg/mL) and/or neomycin (0.3 mg/mL) for
8 days. Transduced cells were seeded at clonal density, and
selected individual clones were isolated from each popula-
tion. To confirm that immortalized cell line maintained their
myogenic signature, the expression of several myogenic
markers (desmin, neural cell adhesion molecule, and MyoD)
was assessed in proliferating primary and immortalized cell
line. Immortalized cells retain the characteristics of the un-
modified parental population.21 In addition, the ability to dif-
ferentiate into myotubes, using immunostaining with MF20
antibody, which recognizes all skeletal-muscle myosin heavy
chains (MHC), was investigated. Differentiation into
myotubes was initiated at 90% confluence by switching to dif-
ferentiation medium [DM; Dulbecco’s modified Eagle’s me-
dium supplemented 50 μg/mL gentamycin (Invitrogen)] for
3 days.
Histology and immunofluorescence analysis
Muscle samples were mounted in tissue freezing medium
(tragacanth paste) and snap frozen in nitrogen-cooled
isopentane. The sections, 10 μm thick, were mounted on
Histobond Adhesion Microslides (Marienfeld, Lauda-
Königshofen, Germany). For the haematoxylin and eosin
(HE), succinate dehydrogenase (SDH), and Masson’s
trichrome stains, serial cryostat sections were stained follow-
ing standard protocols. Muscle sections for immunofluores-
cence analysis were permeabilized and blocked with PBS
with Triton X-100 and Tween 20 (PBT) (1% Triton X-100, 1%
Tween-20, 5% heat inactivated goat serum, 0.2% bovine se-
rum albumin in PBS) for 30 min and incubated with primary
antibodies diluted in PBT overnight at 4°C, washed with
PBS, and then incubated with a mixture of appropriate sec-
ondary antibodies for 1 h at room temperature. Primary
and secondary antibodies used are listed in Table S1. 40,6-
Diamidino-2-phenylindole was used to counterstain the cell
nuclei (Life Technologies, Thermo Fisher Scientific, MA,
USA). Compiled images were used to reconstruct a view of
the entire TA muscle. This compilation was used for quantifi-
cation of centrally located nuclei (CLN), number of myofibres,
cross-sectional area (CSA), and fibre type analysis using
ImageJ64 analysis software. Formalin-fixed kidneys and livers
were paraffin-embedded, and 4 μm longitudinal and sagittal
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sections were cut and stained with HE following a standard
protocol. For analysis of cultured cells, the DMD cells were
cultured on coverslips and differentiated into myotubes.
The intact cells were fixed with ethanol, washed, perme-
abilized, and blocked with PBT, and then stained with primary
antibody diluted in PBT overnight at 4°C. The cells were then
washed and incubated with secondary antibody for 1 h at
room temperature. 40,6-Diamidino-2-phenylindole was used
to counterstain the cell nuclei (Life Technologies). Five fields
from three independent experiments were randomly se-
lected for each treatment. The differentiation grade was eval-
uated based on the number of MHC positive cells above total
nuclei. The number of nuclei within individual myotubes (≥3
nuclei) was counted for 20–50 myotubes. The digital images
of the cell cultures were acquired with a Leica TCS-SP8 spec-
tral confocal microscope (Leica Microsystems, Heidelberg,
Germany).
Immunoblot analysis
Protein was isolated from cells or tissue using ice-cold
radioimmunoprecipitation assay buffer [50 mmol/L Tris–HCl
(pH 7.2), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% (v/v) NP-40,
0.25% (w/v) Na-deoxycholate, protease inhibitor cocktail
(Sigma Chemical), phosphatase inhibitor cocktail (Sigma
Chemical)]. The lysates were clarified by centrifugation
(14 000× g for 15 min at 4°C), and the protein concentration
was quantified using the QuantiProTM BCA assay kit (Sigma
Chemical). For immunoblotting, equal amounts of protein
were fractionated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred onto nitrocellulose mem-
branes. Primary and secondary antibodies used are listed in
Table S1. Immunoreactive bands were detected by enhanced
chemiluminescence (Pierce ECL Western Blotting Substrate,
Thermo Fisher Scientific, Rockford, IL, USA).
RNA extraction, cDNA synthesis, and quantitative
real-time PCR
Total RNA was extracted from TA muscle using TRIzol reagent
according to the manufacturer’s instructions (MRC, Cincin-
nati, OH, USA). After DNase I treatment (Thermo Fisher Scien-
tific, Waltham, MA, USA), 0.5 μg of total RNA was reverse
transcribed using High-Capacity cDNA Reverse Transcription
Kits (Applied Biosystems, Thermo Fisher Scientific, Waltham,
MA, USA). Real-time PCR was carried out in Applied
Biosystems StepOnePlusTM Real-Time PCR System (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA)
using Luminaris HiGreen qPCR Master Mix (Thermo Fisher
Scientific, Waltham, MA, USA). The 2ΔΔCt method was used
to analyse the relative changes in each gene’s expression nor-
malized against the housekeeping 40S ribosomal protein S20
rRNA expression.22 Sequences of the primers used in this
study were as follows: AchRα, Fw 50-CCACAGACTCAGGGGA
GAAG-30 and Rv 50-AACGGTGGTGTGTGTTGATG-30; AchRε,
Fw 50-CAATGCCAATCCAGACACTG-30 and Rv 50-CCCTGCTTCTC
CTGACACTC-30; AchRδ, Fw 50-CATCGAGTGGATCATCATTGAC-
30 and Rv 50-CGGCGGATGATAAGGTAGAA-30; muscle-specific
receptor tyrosine kinase (MuSK), Fw 50-TGAGAACTGCCCCT
TGGAACT-30and Rv 50-GGGTCTATCAGCAGGCAGCTT-30; ErbB1,
Fw 50-GACCTTCACATCCTGCCAGT-3 and Rv 50GCATGGAGGTC
AGTCCAGTT-30; and ribosomal protein S20, Fw 50-CCATGG
CATTTAAAGATACCG-30 and Rv 50-AACCTTCTCCAGCGACTTC
AC-30.
Blood measurements
Blood samples were collected from tail bleeds under general
anaesthesia at the end of the treatment. The blood was col-
lected in heparinized tubes, serum was isolated, and creatine
kinase (CK), alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase, bilirubin, and urea
levels were performed by the Central Laboratory at Hospital
Clínico Universitario de Santiago de Compostela (Santiago
de Compostela, Spain).
Statistical analysis
All values are presented as mean ± SEM. Statistical analyses
were performed using GraphPad Prism (version 5.0b;
GraphPad Software, San Diego, CA, USA). Statistical signifi-
cance was assessed by one-way analysis of variance with
the Bonferroni post-test or Student’s unpaired t-test, with
P < 0.05 being considered significant (*,#).
Results
Obestatin treatment improves muscle strength in
mdx mice
As a first step, we investigated the protein expression of
preproghrelin, as precursor of obestatin, and GPR39 in the
TA muscles of mdx mice at different ages (4-, 8-, and 18-
week-old mdx mice) by immunoblot analysis. As shown in
Figure 1A, we found an inverse relationship between muscle
preproghrelin and GPR39 protein expression with ageing. The
age-related changes prompted us to examine the effects of
exogenous obestatin in 8-week-old mdx mice. Obestatin
treatment was performed via intramuscular injection into
the TA muscles every 72 h during 30 days [500 nmol/kg body
weight (n = 5); referred as obestatin group; Figure 1B] with
sampling at 12 weeks the age, as previously described.15 Re-
sults from this group were compared with control vehicle-
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treated mdx mice (PBS; n = 5; now referred as control group)
under the same conditions. As functional strength is one the
measurable outcomes frequently used for DMD patients, we
investigated force production in the TA muscles. No signifi-
cant differences in twitch force were found between the
obestatin-treated and control groups (20.0 ± 1.5 mN/mm2
and 20.5 ± 1.7 mN/mm2, respectively; Figure 1C). In contrast,
mean tetanic specific force was higher in obestatin-treated
TA regarding control TA muscles (51.8 ± 0.4 mN/mm2 and
39.0 ± 3.2 mN/mm2, respectively; Figure 1D), representing a
33.0% ± 1.5% increase in relation to control muscles. The
force-frequency curves for TA muscle displayed improved
force generation beginning at 140 Hz and continuing through
200 Hz relative to PBS (Figure 1E).
The wet-weights of TA muscles were measured. Interest-
ingly, we did not observe significant differences in the aver-
age muscle mass of the TA treated with obestatin relative
to control (Figure 1F). Furthermore, we analysed the serum
levels of CK, a skeletal muscle enzyme released during fibre
degeneration (Figure 1G). We observed a significant decrease
in the average CK levels of mdx mice treated with obestatin
relative to control mice (16 180.0 ± 5968.0 U/L and
39 290.0 ± 7979 U/L, respectively), suggesting a decrease in
the level and severity of muscle damage. The TA muscles
from obestatin-treated or control mdx mice were stained
with HE and analysed for the presence of CLN (Figure 1H),
myofibre number (Figure 1I), and CSA (Figure 1J and 1K). A
10% ± 1.2% decrease in CLN percentage was observed in
the obestatin-treated mdx TA muscle compared with control
(Figure 1H). We found that the average number of myofibres
in the obestatin-treated mdx mice (2067.0 ± 40.5) was only
slightly lower compared with control animals
(2191.0 ± 68.0) (Figure 1I), but this difference was not statis-
tically significant. CSA was 23.5% ± 3.2% larger in control
Figure 1 Obestatin treatment improves Duchenne muscular dystrophy (DMD) phenotype inmdxmice. (A) Protein levels of preproghrelin, precursor of
obestatin, and GPR39 in the tibialis anterior (TA) muscles ofmdxmice of different ages (4-, 8-, and 18-week-old mdx mice; n = 3 per age group). Protein
levels were analysed by immunoblot, and data were expressed as arbitrary units (mean ± SEM; *,#P < 0.05 vs. control values) obtained from intensity
scans. (B) A schematic diagram of intramuscular administration of obestatin (500 nmol/kg body weight each 72 h; n = 5) or vehicle (control; n = 5) in TA
frommdxmice. (C) Effect of intramuscular injection of obestatin or vehicle on twitch force at 30 days. (D) Effect of intramuscular injection of obestatin
or vehicle on tetanic force at 30 days. (E) Force-frequency curve of TA muscles in obestatin-treated or vehicle-treated groups. (F) TA muscle weight
after 30 days of treatment with vehicle or obestatin. (G) Serum creatine kinase (CK) levels after 30 days of treatment with vehicle or obestatin. (H)
Left panel, representative haematoxylin and eosin staining from vehicle-treated and obestatin-treated muscles TA. Right panel, quantitation of
myofibres with CNL from TA muscles. Data are shown as % of myofibres with centrally located nuclei (CLN). (I) Quantification of number of myofibres
in TA muscles after 30 days of treatment with vehicle or obestatin. (J) Cross-sectional area of muscle fibres from TA muscles after intramuscular in-
jection of obestatin or vehicle at 30 days (mean ± SEM; n = 5 animals per group; *P < 0.05 vs. control values). (K) Distribution of fibre diameter from
vehicle-treated and obestatin-treated mice. Data are expressed as % of myofibres. From (C) to (K), data are represented as mean ± SEM and *P < 0.05
vs. control values. CSA, cross-sectional area; PBS, phosphate-buffered saline.
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mice compared with obestatin-treated mice (Figure 1J): mice
treated with obestatin presented an increase in the percent-
age of small myofibres between 5 and 20 × 102 μm2 (Figure
1K). Together, these data show that mdx mice treated with
obestatin present an improvement in functional outcome
measures (muscle strength) and a small increase in the num-
ber of small diameter fibres.
Obestatin regulates oxidative fibre expression
On histological examination of TA (fast/glycolytic muscle)
from obestatin-treated animals, we observed a marked in-
crease in the relative density of SDH positive fibres (SDH+,
oxidative fibres), compared with control mdx mice, with a
corresponding decrease in SDH negative fibres (SDH,
Figure 2A). Quantitation of the total fibre number revealed
an increase of 23.0% ± 1.9% in SDH+ fibres, oxidative fibre
type, in obestatin-treated group relative to control group.
On the other hand, the number of SDH fibres was decreased
by 23.0% ± 6.5% in obestatin-treated TA muscles relative to
control muscles. This oxidative fibre-type switch was
associated with significant increase in the expression of pro-
teins involved in the mitochondrial biogenesis pathway, such
as Cytochrome C (40.3% ± 7.0%), mitochondrial uncoupling
protein 3 (136.5% ± 7.1%), mitochondrial transcription factor
A (81.1% ± 17.0%), PGC1α (58.5% ± 14.0%), and carnitine
palmitoyltransferase-1 (50.36% ± 13.1%), in obestatin-treated
mdx mice as compared with control animals (Figure 2B and
2C).
The slow type I and the fast type IIa, IIb, and IIx constitute
the four basic fibre types, classically identified based on their
MHC isoform content.23,24 Muscle fibre-type assessment by
immunofluorescence (Figure 3A) revealed that obestatin in-
creased by 25.2% ± 1.7% the number of type I fibres relative
to controls (Figure 3A). These TA muscles had a reduction in
type IIx fibres compared with control, while no significant dif-
ferences were observed in type IIa and IIb fibres (Figure 3A).
The CSA of type I fibres was significantly increased in
obestatin-treated TA muscles compared with control mice
(four-fold increase; Figure 3A). Interestingly, the type IIb fi-
bres had a significantly larger CSA in obestatin-treated mice
than control mice, whereas no significant differences were
observed in type IIa and IIx (Figure 3A).
Figure 2 Obestatin treatment increases oxidative fibre density. (A) Upper panel, representative succinate dehydrogenase (SDH) staining from tibialis
anterior (TA) from control muscles and obestatin-treated muscles at 30 days. Bottom panel, quantitation of SDH+ and SDH muscle fibres from TA
muscles. Data were expressed as mean ± SEM (
*
P < 0.05 vs. control values). (B) Immunoblot analysis of Cytochrome C and uncoupling protein 3
(UCP3) in TA muscles after intramuscular injection of obestatin or control (phosphate-buffered saline) at 30 days. (C) Immunoblot analysis of mitochon-
drial transcription factor A (mtTFA), carnitine palmitoyltransferase-1 (CPT1), and proliferator-activated receptor-gamma coactivator 1α (PGC1α) in TA
muscles after intramuscular injection of obestatin or control (phosphate-buffered saline) at 30 days. In (B) and (C), protein level was expressed as fold
of control TA muscles, and immunoblots are representative of the mean value. Data were expressed as mean ± SEM obtained from intensity scans
(
*
P < 0.05 vs. control values).
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Slow and oxidative myofibre identity is regulated by the
balance between positive and negative signalling by Mef2
and the class II HDAC proteins, respectively.25 Indeed, west-
ern blot analysis of obestatin-treated TA muscles demon-
strated the up-regulation of Mef2A and Mef2C protein
expression (92.0% ± 16.0% and 52.0% ± 7.0%, respectively;
Figure 3B). However, the activity of Mef2 is tightly regulated
through association with HDACs, which act as signal-
dependent repressors of gene expression. HDAC phosphory-
lation in response to differentiation signals or motor
innervation provides docking sites for the 14-3-3 chaperone
protein that leads to nuclear export of HDACs enabling
Mef2 to activate the slow myofibre gene programme.26–28
Consistent with this, obestatin treatment resulted in
markedly elevated levels of HDAC5 [pHDAC5(S259);
149.2% ± 29.5%] and HDAC7 [pHDAC7(S155); 93% ± 32.0%]
phosphorylation, but no significant differences were ob-
served in HDAC4 phosphorylation (Figure 3C). Consistent
with the role of Mef2 as a transcriptional regulator of the
slow-fibre phenotype, the expression of slow troponin I (tro-
ponin I-SS) was much higher in obestatin-treated muscles
(147.0% ± 27%) than in control muscles, whereas fast
troponin I (troponin I-FS) expression was decreased
(51.0% ± 4.0%; Figure 3D). Therefore, the phosphorylation
of HDAC5/7 potentially regulated by obestatin signalling pro-
vides a mechanism for the modulation of Mef2 target genes
to promote slow and oxidative myofibres.
Obestatin modulates molecular markers of protein
synthesis and degradation
In terms of protein degradation, obestatin treatment led to a
43.6% ± 7.6% and 42.8% ± 14.0% decrease in the expression
of the ubiquitin E3-ligases MuRF1 and MAFbx, respectively
(Figure 4A). One mechanism by which obestatin reduces the
expression of the ubiquitin E3 ligases is the phosphorylation
and subsequent nuclear exclusion of FoxO family members.16
As shown in Figure 4B, obestatin-treated mice showed a strik-
ing increase in FoxO1 phosphorylation at T24 [pFoxO1 (T24);
130.4% ± 18.0%] and FoxO4 phosphorylation at T28 [pFoxO4
(T28); 378.6% ± 59.5%] related to control mice but did not
change basal FoxO3a phosphorylation at T32 [pFoxO3
(T32)]. This suggests that post-translational modifications of
Figure 3 Obestatin stimulates fast to slow twitch fibre type shifting in mdx mice. (A) Left panel, representative images of control-treated and
obestatin-treated tibialis anterior (TA) muscles showing myosin heavy chains (MHC) expression. Mice muscle serial cross section incubated with a pri-
mary antibody against MHCI, MHCIIa, MHCIIb, or MHCIIx, followed by incubation with appropriate fluorescent-conjugated secondary antibody. Right
panel, quantitation of fibre types (upper panel) and cross-sectional area (CSA) (bottom panel). Data are shown as mean ± SEM of five animals per
group (*P < 0.05 vs. control values). (B) Immunoblot analysis of Mef2A and Mef2C in TA muscles after intramuscular injection of obestatin or vehicle
(phosphate-buffered saline, control) at 30 days. (C) Immunoblot analysis of pHDAC4(S246), pHDAC5(S259), pHDAC7(S155), and HDAC4 in TA muscles
after intramuscular injection of obestatin or control (phosphate-buffered saline) at 30 days. (D) Expression of the slow-fibre-specific troponin I-SS and
fast-fibre-specific troponin I-FS in TA muscles after intramuscular injection of obestatin or vehicle at 30 days. In (B) to (D), protein level was expressed
as fold of control TA muscles, and immunoblots are representative of the mean value. Data were expressed as mean ± SEM (n = 5 per group) obtained
from intensity scans (*P < 0.05 vs. control values). HDAC, histone deacetylases; Mef2, myocyte enhancer factor-2.
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FoxO4 and FoxO1 could play a role in directing FoxO activity
in response to obestatin and, thus, to control the E3 ubiquitin
ligases MuRF1 and MAFbx.
The down-regulation of MuRF1 and MAFbx expression was
concomitant with the activation of positive regulators of pro-
tein synthesis. Obestatin increased S6K1 phosphorylation at
S371 [pS6K1(S371)] and its downstream target, the ribosomal
protein S6 phosphorylation at S240/244 [pS6(S240/244)] by
152.9% ± 39.0% and 109.0% ± 23.4%, respectively, compared
with untreated mice (Figure 4C and 4D). Furthermore,
obestatin markedly promoted 4E-BP1 hyperphosphorylation
at T70 [p4E-BP1(T70)], especially concerning the γ form
(71.2% ± 11.4%), altering the basal phosphorylation of β
and γ forms at T37/T46 [p4E-BP1(T37/46); 49.4% ± 7.8%
and 25.5% ± 9.2%, respectively] (Figure 4E). Consequently,
obestatin signalling regulates critical components of the
anabolic machinery for protein synthesis, S6K1 and 4E-
BP1,29 in dystrophic conditions.
Obestatin-treated mdx mice have increased
sarcolemma adhesion protein components
The improvements in mdx mice under obestatin treatment
could be associated with restoration or increased abundance
of sarcolemma adhesion protein components. Analysis by im-
munoblot of some of these proteins showed that obestatin
treatment increased the expression of utrophin by
74.0% ± 20.3% compared with untreated mice (Figure 5A).
This up-regulation was concomitant with increased expres-
sion of α-syntrophin and β-dystroglycan compared with un-
treated mice (38.8% ± 6.9% and 96.1% ± 26.0%,
Figure 4 Obestatin treatment protects from atrophy with induction of protein synthesis signalling inmdxmice. (A) Immunoblot analysis of MuRF1 and
MAFbx in tibialis anterior (TA) muscles after intramuscular injection of obestatin or control. (B) Immunoblot analysis of the phosphorylation partner of
FoxO3, FoxO1, and FoxO4 in TA muscles after intramuscular injection of obestatin or vehicle (phosphate-buffered saline, control) at 30 days. (C) Anal-
ysis of pS6K1(S6371) and S6K1 in TA muscles after intramuscular injection of obestatin or vehicle at 30 days. (D) Immunoblot analysis of pS6(S240/244)
and S6 in TA muscles after intramuscular injection of obestatin or vehicle. (E) Analysis of p4E-BP1(T70), p4E-BP1(T37/46), and 4E-BP1 in TA muscles
after intramuscular injection of obestatin or vehicle (phosphate-buffered saline, control) by immunoblot. In (A) to (E), protein level was expressed
as fold of control TA muscles. Immunoblots are representative of the mean value (n = 5 per group). Data were expressed as mean ± SEM obtained
from intensity scans (*P < 0.05 vs. control values).
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respectively; Figure 5A) but did not change basal neuronal ni-
tric oxide synthase (NOS1) expression. In addition, obestatin
treatment led to increased levels of α7-integrin and β1D-
integrin (35.2% ± 4.8% and 37.9% ± 5.8% compared with con-
trol mice, respectively; Figure 5A). Confocal imaging analysis
of histological sections from obestatin-treated TAs showed
a noticeable increase in the expression of utrophin in the
extrasynaptic sarcolemma (Figure 5B). In contrast, utrophin
was expressed at low levels on the extrasynaptic sarco-
lemma, being mainly restricted to NMJ in untreated muscles
(Figure 5B). Importantly, we found an increase in α7-integrin
and β1D-integrin proteins at the sarcolemma in obestatin-
treated mice when compared with untreated (Figure 5C and
5D, respectively). These data, together with the significant
decrease in CK, suggest that obestatin treatment protects
the fibres by reducing the degradation of the sarcolemma
Figure 5 Obestatin regulates the complex of proteins that acts as link between the muscle fibres and the extracellular matrix. (A) Expression analysis of
utrophin, α-syntrophin, ß-dystroglycan, nitric oxide synthase (NOS1), α7-integrin, and ß1D-integrin in tibialis anterior (TA) muscles after intramuscular
injection of obestatin or control at 30 days. Protein level was expressed as fold of control. Immunoblots are representative of the mean value. Data
were expressed as mean ± SEM obtained from intensity scans (
*
P < 0.05 vs. control values). (B) Representative immunofluorescence images of
obestatin-treated or control TA muscles [phosphate-buffered saline (PBS)] at 30 days showing utrophin and neuromuscular junctions (α-bungarotoxin)
expression. Mouse muscle serial cross sections were incubated with primary antibodies against utrophin and α-bungarotoxin, followed by incubation
with appropriate fluorescent-conjugated secondary. (C) Representative immunofluorescence images from obestatin-treated or control TA muscles
showing α7-integrin expression at 30 days. (D) Representative immunofluorescence images of obestatin-treated or control (PBS) TA muscles showing
ß1D-integrin expression at 30 days. (E) Relative mRNA levels of acetylcholine receptor (AchR) subunits α, δ, ε, and Musk, Erbb1 in obestatin-treated
(500 nmol/kg/72 h) or control TA muscles (PBS, control) at 30 days (n = 5 per group). Data were expressed as mean ± SEM (*P < 0.05 vs. control
values).
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adhesion components in skeletal muscle of mdx mice,
thereby increasing membrane stability.
Obestatin enhances acetylcholine receptor α gene
We further tested whether obestatin regulates the NMJ
gene expression, based on the regulatory role of PGC1α
in the NMJ program.30 To test this hypothesis, we mea-
sured the expression levels of acetylcholine receptor (AchR)
α subunit (AchRα), ε subunit (AchRε), δ subunit (AchRδ),
muscle-specific receptor tyrosine kinase (MuSK), and recep-
tor tyrosine-protein kinase erbb-1 (ErbB1) by quantitative
real-time PCR. We detected increased levels of AchRα
(165.0% ± 73%) but not AchRε, AchRδ, MuSK, or ErbB1 in
obestatin-treated mice relative to controls (Figure 5E).
Figure 6 Obestatin regulates muscle tissue fibrosis and necrosis in mdx mice. (A) Representative images of the histological analysis from sections
stained with Masson’s trichrome staining are shown from obestatin-treated or control tibialis anterior (TA) muscles (control) at 30 days. (B) Expression
analysis of connective tissue growth factor (CTGF), α-smooth muscle actin (α-SMA), and collagen type I (Coll I) in TA muscles after intramuscular in-
jection of obestatin or control. Protein level was expressed as fold of control TA muscles, and immunoblots are representative of the mean value. Data
were expressed as mean ± SEM (n = 5 per group) obtained from intensity scans (*P < 0.05 vs. control values). (C) Left panel, representative images of
IgG staining and laminin of obestatin-treated TA muscles or control. Right panel, quantification of IgG+ fibres in obestatin-treated or control (phos-
phate-buffered saline) TA muscles at 30 days (n = 5 per group). Data were expressed as mean ± SEM (
*
P < 0.05 vs. control values).
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Obestatin alleviates the phenotype of muscular
dystrophy
We determined the rate of interstitial fibrotic regions by
Masson’s trichrome staining. While fibrosis typically only be-
comes prominent in older mdx mice, even the mild degree of
tissue fibrosis developed at 12 weeks of age was reduced in
TAs of obestatin-treated mice (Figure 6A). Consistent with
this, the expression of fibrosis-associated molecules, connec-
tive tissue growth factor (CTGF), α-smooth muscle actin
(α-SMA), and collagen type I (Coll I) proteins was decreased
by 45.0% ± 5.0%, 33% ± 6.0%, and 26.5% ± 8.4% in
obestatin-treated muscles, compared with control mice,
respectively (Figure 6B). To further assess the extent of dam-
aged myofibres, we quantified the number of IgG-positive
damaged fibres by immunofluorescence31 and found a
16-fold decrease in the number of damaged fibres in
obestatin-treated muscles (Figure 6C).
In order to assess potential toxicity of obestatin treatment,
plasma was collected from mice at the end of treatment, and
organs were harvested for toxicological analysis. Compared
with untreated mdx mice, histological HE staining of kidney
and liver tissue sections of obestatin-treated mice showed
no detectable effect on cells in those tissues nor any increase
in the amount of infiltrating immune cells, suggesting the ab-
sence of any toxic effect (Figure S1a and S1b, respectively).
Serum levels of urea, bilirubin, and alkaline phosphatase
showed no significant difference compared with mdx un-
treated mice (Figure S1c to S1e, respectively). Interestingly,
AST and ALT liver enzymes were significantly reduced in
obestatin-treated mice compared with untreated mdx con-
trols (Figure S1f and S1g, respectively). Overall, these results
indicate that during the time course of the experiment,
obestatin did not induce any overt hepatic or renal toxicity
in mdx mice.
Obestatin regulates sarcolemma adhesion protein
components in human immortalized Duchenne
muscular dystrophy myoblasts
To validate whether obestatin signalling and effect are con-
served between human and mouse, we used an in vitro cell
culture model of human DMD skeletal muscle cells, which is
the only model available to assess signalling in a human con-
text (for details, see section). To assess the effect of human
obestatin on differentiation, DMD myoblasts were switched
to DM supplemented with obestatin at a range of concentra-
tions (0.01–100 nM) for 3 days. As shown in Figure 7A, the
protein levels of myogenin, as detected by immunoblot, were
up-regulated at a maximal level in the presence of 10 nM
obestatin. Insulin (1.72 μM) was used as the positive control
based on its role in the control of skeletal muscle growth and
in the regulation of muscle mass.14 To investigate whether
obestatin stimulated hypertrophic growth, the DMD cells
were treated with obestatin in DM for 3 days (Figure 7B).
The myotube area was larger in the obestatin-treated cells
(DM + obestatin; 992.32 ± 40.31 μm2) as compared with un-
treated conditions (DM; 687.42 ± 31.02 μm2) or insulin-
treated cells (DM + insulin; 879.76 ± 44.40 μm2) at 72 h after
differentiation (Figure 7B). Furthermore, the number of
myonuclei per MHC-positive myotube (MHC+) was 20 ± 1.79
in obestatin-treated cells vs. 5 ± 0.19 in control cells or
8 ± 0.67 in insulin-treated cells (Figure 7C). Immunoblot anal-
ysis of total-MHC, slow-MHC, and fast-MHC demonstrated a
robust increase in the protein levels of total-MHC and slow-
MHC in the presence of 10 nM obestatin (75.0% ± 2.2% and
52% ± 6.0% compared with untreated cells; Figure 7D) with
a significant decrease in the levels of fast-MHC (Figure 7D).
Immunoblot analyses of utrophin, α-syntrophin, and ß-
dystroglycan revealed elevated protein expression in
obestatin-treated cells as compared with untreated cells at
72 h of differentiation (36.7% ± 3.0%, 42.1% ± 3.0%, and
26.9% ± 6.5%, respectively; Figure 7E). The protein levels of
NOS1, α7-integrin, and ß1D-integrin were also up-regulated
at 72 h after differentiation (16.7% ± 2.0%, 30.5% ± 3.0%,
and 32.7% ± 2.0%; Figure 7E). Thus, human DMD myotubes
underwent a functional switch towards an oxidative fibre
type orchestrated by obestatin signalling during in vitro
myogenesis. In addition, the up-regulation of the expression
of sarcolemma adhesion components is also confirmed in this
system, thereby increasing membrane stability.
Discussion
In this report, we have shown that obestatin ameliorates the
DMD phenotype. Obestatin treatment results in a fast-to-
slow fibre type switch that translates into an increase in oxi-
dative fibres. Obestatin acts through both HDAC/Mef2 and
PGC1α mechanisms, thereby controlling the establishment
of oxidative muscle fibres. Moreover, obestatin signalling reg-
ulates muscle atrophy through regulation of ubiquitin E3-
ligases expression, MAFbx, and MuRF1, through inactivation
of FoxO4 and FoxO1. Notably, obestatin leads to a stabiliza-
tion of the sarcolemma of mdx skeletal muscle through the
expression of utrophin, α-syntrophin, β-dystroglycan, and
α7β1-integrin proteins. This observation correlates with the
decrease in the levels of serum CK, AST, and ALT, signs that
indicate a partial rescue of muscle tissue necrosis. Further-
more, treatment with obestatin reduces muscle fibrosis. All
these effects provoke a substantial improvement in skeletal
muscle physiological function, in terms of specific force pro-
duction. These actions acquire more relevance considering
the age-related loss of preproghrelin expression, and thus
obestatin, in dystrophin deficient mdx mice.
Obestatin attenuates histopathological and biochemical
features of muscular dystrophy in mdx mice. Rates of
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myofibre central nucleation, tissue fibrosis, and tissue ne-
crosis (evaluated as IgG+ myofibres) were reduced in mdx
mice treated with obestatin. In addition, CK, ALT, and AST
levels were significantly reduced compared with untreated
mice, which also strongly suggest a decrease in muscle fi-
bre damage. This improvement correlates with improved
muscle function because obestatin-treated mice show a sig-
nificant increase in muscle strength, as determined by
Figure 7 Obestatin signalling regulates differentiation of human Duchenne muscular dystrophy (DMD) cells. (A) Dose–response effect of obestatin
(0.01–100 nM) or insulin (1.72 μM) on differentiating human DMD cells. Levels of myogenin were represented as a fold of respective expression in
differentiation medium (DM) (72 h post-differentiation). (B) Left panel, immunofluorescence detection of myosin heavy chains (MHC) and 40,6-
diamidino-2-phenylindole (DAPI) in human DMD myotube cells under DM (control), DM + obestatin (10 nM), or DMD + insulin (1.72 μM) at the
72 h point after stimulation. Right panel, the differentiation grade was evaluated based on the myotube area and distribution. Data were expressed
as mean ± SEM (
*
P < 0.05 vs. control values). (C) Quantification of the number of myonuclei in MHC
+
cells in human DMD myotube cells under DM
(control), DM + obestatin (10 nM), or DMD + insulin (1.72 μM) at the 72 h point after stimulation. Data were expressed as mean ± SEM (*P < 0.05 vs.
control values). (D) Immunoblot analysis of MHC, slow-MHC and fast-MHC, in human DMD myotubes at the 72 h point under DM (control),
DM + obestatin (10 nM), or DMD + insulin (1.72 μM). (E) Effect of obestatin (10 nM) on utrophin, α-syntrophin, ß-dystroglycan, nitric oxide synthase
(NOS1), α7-integrin, and ß1D-integrin expression on differentiating human DMD cells. In (A), (D), and (E), protein level was expressed as optical density
arbitrary units obtained from intensity scans. Immunoblots are representative of the mean value. Data were expressed as mean ± SEM (*P < 0.05 vs.
control values).
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generation of specific force. Because obestatin controls the
fibre type determination,15 some of this gain-of-function
may be linked to a conversion of fast-twitch to slow-twitch
fibres, which are more resistant to degeneration. The slow
and oxidative myofibre identity is governed by the balance
between positive and negative signalling by Mef2 and class
II HDACs, respectively.25 Obestatin increases class II HDAC
phosphorylation, thus leading to nuclear export of HDACs
and allowing sustained activation of Mef2, which promotes
the establishment of slow and oxidative myofibres, i.e.
MHC type I and troponin I-SS. The increase in oxidative fi-
bre density triggered by obestatin signalling is accompanied
by significant changes in known regulators of mitochondrial
function, such as Cytochrome C, uncoupling protein 3, and
carnitine palmitoyltransferase-1. This improved mitochon-
drial capacity is concomitant to an increased expression
of PGC1α, a master regulator of mitochondrial gene expres-
sion involved in activation of mitochondrial biogenesis and
oxidative metabolism.32 Mechanistically, PGC1α regulates fi-
bre type switching through the coactivation of Mef2.33 Fur-
thermore, Mef2 regulates PGC1α expression through an
autoregulatory loop.28 Therefore, Mef2 operates as a nodal
point for the control of multiple downstream transcrip-
tional regulators of the slow-fibre phenotype and PGC1α
expression. Our data show that obestatin treatment trig-
gers an up-regulation of AchRα, a component of the NMJ
gene program. This observation correlates with previous
observations made with PGC1α transgenic mice in which
PGC1α was shown to regulate the NMJ genes.30 In addi-
tion, obestatin has an anti-atrophic effect by regulating
the expression levels of the two E3 ubiquitin ligases, hall-
marks of skeletal muscle atrophy, MAFbx and MuRF1. Al-
though the exact mechanism of this effect is unknown in
DMD, it is clear that obestatin inhibits the function of the
pro-atrophic transcription factors FoxO1 and FoxO4 and
blunts the induction of the atrogenes MAFbx and MuRF1.
Interestingly, the obestatin action is not due to an effect
on the FoxO3, which appears to be phosphorylated or
inactivated under basal conditions. Recent data have shown
that Akt/mTOR activation combined with PKD/CAMKII/
AMPK inactivation by the obestatin signalling is required
to inhibit FoxO-dependent atrogenes in catabolic processes
provoked by glucocorticoids.16 This is consistent with the
activation of S6K1 and by eIF4E availability, through phos-
phorylation of 4E-BP1, key regulators of protein synthesis,
which shift the balance from protein degradation to protein
synthesis in obestatin-treated mice. Despite these results,
which suggest a role for obestatin in the regulation of mus-
cle hypertrophy, the mean value of CSA was larger in con-
trol than in obestatin-treated mdx mice. It is tempting to
assume that the obestatin/GPR39 system operates at first
to induce the adaptive response of dystrophic myofibres
by regulating fibre-type switch or transition in myosin iso-
form expression. In this scenario, the activation of positive
regulators of protein synthesis reflects a reprogramming of
gene transcription that leads to a remodelling of the fibre
contractile properties (fast-slow transitions) and the meta-
bolic profile (glycolytic-oxidative transitions). Indeed, here,
we show that in obestatin-treated muscles, the number of
MHCI+ myofibres increased with the concomitant reduction
of the MHCII+ myofibres, MHCIIb, and MHCIIx, while the
average number of myofibres remains unchanged. The fact
that obestatin signalling was insufficient to increase muscle
growth in this situation, despite being able to act on S6K1
and 4E-BP1, implies that there are other Akt/mTOR-
dependent signalling events that are required for muscle
growth.34
The absence of dystrophin leads to a decrease and a delo-
calization of dystrophin-associated proteins with the conse-
quent sarcolemma instability and damage as muscle fibres
detach from the laminin-rich basal lamina during contrac-
tion.35 An alternative approach to restoring dystrophin defi-
ciency is to up-regulate the expression of utrophin based on
the evidence for functional redundancy between these two
proteins.36 Indeed, utrophin shares a high degree of se-
quence identity with dystrophin and also associates with
members of the dystrophin-associated protein complex.37
Utrophin is restricted to neuromuscular and myotendinous
junctions in adult muscle, but during embryonic development
and in patients with DMD, it is localized at the sarcolemma
when dystrophin is absent or present only at low levels. Stud-
ies in animal models have provided compelling evidence that
utrophin functions in these scenarios directly to protect the
muscle against dystrophic degeneration.36 Our results indi-
cate that obestatin signalling regulates utrophin expression.
Specifically, mdx mice treated for 30 days with obestatin
showed an increase in utrophin levels compared with control
mdxmice, which are localized throughout the entire length of
the sarcolemma. These results are consistent with the pro-
motion of the slow oxidative myogenic programme by
obestatin signalling. Indeed, metabolic changes to the muscle
can also influence utrophin expression.38 Given the demon-
strated role of PGC1α in regulating utrophin transcrip-
tion,39–41 we speculate that inhibition of HDAC activity
through obestatin signalling results in increased Mef2 levels
and stimulation of PGC1α expression leading to utrophin
up-regulation. In addition, the up-regulation of utrophin ex-
pression and its localization at the sarcolemma may stimulate
the expression and correct localization of the dystrophin gly-
coprotein complex, i.e. α-syntrophin and ß-dystroglycan, ex-
cept for NOS1, which does not show significant differences
with control mice. It has been previously established that dys-
trophin localizes NOS1 to the sarcolemma, whereas utrophin
does not.42 The implication of this is uncertain, given that
there may be compensatory pathways for the lack of
NOS1.36,43 In addition to the enhancement of structural pro-
teins like utrophin, obestatin also regulates α7β1 integrin ex-
pression, a laminin-binding protein that contributes to the
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overall integrity of the sarcolemma.44 The α7β1 integrin has
structural and signalling functions that contribute to muscle
development and physiology.45 Loss of the α7 integrin in
dystrophin-deficient mdx mice leads to a severe dystrophic
phenotype,44 while transgenic overexpression of the α7β1
integrin ameliorates disease pathology and extends the lon-
gevity of severe dystrophic models.46 Taken together, our
data suggest that the up-regulation of utrophin and α7β1
macromolecular complexes in obestatin-treated mdx mice
protect myofibres from contraction-induced muscle injury.
This action stabilizes the link between the sarcolemma and
the extracellular matrix in mdx mice.
The convenience and cost effectiveness of the mdx
mouse leaves it as the model of choice or research into
DMD.47 This convenience is partly counterbalanced by the
fact that the mdx myopathy is plainly not an exact repro-
duction of DMD.48 To remain as close as possible to the
human pathology, human immortalized DMD myoblasts
were used to validate obestatin-signalling pathway. We re-
port here that obestatin favours the recruitment and fusion
of DMD myoblasts into myotubes, as indicated by the in-
creased number of myonuclei in MHC+ cells, with increased
expression of slow-MHC and hypertrophic effect. Further-
more, we show that obestatin acts to increase levels of
both utrophin and α7β1 integrin complexes during the
myogenic differentiation. These findings support and em-
phasize the role of the obestatin signalling into the myo-
genic programme in DMD.
Although there are several promising therapeutic ap-
proaches under investigation for DMD, this pathology will re-
quire a multidisciplinary approach to address its many
features. Our results illustrate how obestatin can restore to
some extent muscle integrity and function in DMD. These
data position obestatin as a potential DMD therapeutic candi-
date not only as an ameliorative treatment to slow the mus-
cle damage but also as part of combinatorial treatment
strategies. In this sense, obestatin-mediated fibre restoration
would allow the maintenance of vector or cell content in the
decisive period between injection and transgene expression
in the dystrophic muscles. For instance, the stability of the
pre-conditioned muscle fibre could help mitigate the loss of
therapeutic vectors in gene therapy and guarantee a higher
therapeutic benefit in restoration of dystrophin in the mus-
cles of DMD patients.9–11 The results presented so far provide
compelling evidence for a potential way of treating DMD.
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